Evidence map›Paper›PMID 40686743›Full record

ArticleAdvances in radiation oncology2025

Definitive Radiation Therapy for Ewing Sarcoma: Outcomes Based on Tumor Volume, Dose, and Fractionation.

Taylor M Weiskittel, William S Harmsen, Anita Mahajan, Ivy A Petersen, Michael G Haddock, Wendy Allen-Rhoades, Steven I Robinson, Nadia N Laack, Safia K Ahmed

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taylor M WeiskittelMolecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.
William S HarmsenBiomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Anita MahajanRadiation Oncology, Mayo Clinic, Rochester, Minnesota.
Ivy A PetersenRadiation Oncology, Mayo Clinic, Rochester, Minnesota.
Michael G HaddockRadiation Oncology, Mayo Clinic, Rochester, Minnesota.
Wendy Allen-RhoadesPediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Steven I RobinsonMedical Oncology, Mayo Clinic, Rochester, Minnesota.
Nadia N LaackRadiation Oncology, Mayo Clinic, Rochester, Minnesota.
Safia K AhmedRadiation Oncology, Mayo Clinic, Phoenix, Arizona.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Dose escalation for definitive radiation therapy (DE-RT) in larger Ewing sarcomas (ESs) is associated with a lower risk of local recurrence. We report treatment and toxicity outcomes in ES tumors treated with DE-RT, including hypofractionated approaches and size stratification of analysis. Methods and Materials: A retrospective review of ES patients treated with DE-RT to doses ≥55.8 Gy was performed. Local failure (LF) with death as a competing risk was assessed. Maximally selected rank statistics were used to determine the optimal stratification of patients by survival using tumor size measurements. Results: In total, 47 patients were analyzed. Twenty-eight patients (59.6%) received DE-RT, of which 6 received hypofractionation. For DE-RT, median equivalent dose in 2 Gy fraction for α/β = 10 was 60 Gy (range, 56.2-62) with conventional fractionation and 62.2 Gy (range, 56.5-67.1) with hypofractionation. Empirically derived size cutoffs identified a subgroup of ultralarge tumors at higher risk of LF defined as >11.8 cm in the longest direction, 569.2 cm Conclusions: DE-RT was associated with a trend toward better LF in all tumors without toxicity or plan quality changes. Ultralarge tumors demonstrated poor LF rates and necessitate further study.

Identifiers

PMID40686743
PMCPMC12272112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.